我们能否使用更低剂量的脂质体两性霉素 B 来治疗黏膜型皮肤利什曼病？
Can we use a lower dose of liposomal amphotericin B for the treatment of mucosal American leishmaniasis?
机构信息
Division of Infectious and Parasitic Diseases, Hospital das Clínicas, University of São Paulo, Medical School, Brazil.
出版信息
Am J Trop Med Hyg. 2011 Nov;85(5):818-9. doi: 10.4269/ajtmh.2011.11-0287.
Abstract
Liposomal amphotericin B has been used as an alternative treatment of mucosal leishmaniasis, but the optimal dose is not established. We retrospectively reviewed the clinical outcome of eight patients with mucosal leishmaniasis treated with liposomal amphotericin B. The mean total dose was 35 mg/kg (range 24-50 mg/kg), which resulted in the healing of all the lesions in all patients and no recurrences were observed during the follow-up period (mean 25 months; range 7-40 months).
摘要
脂质体两性霉素 B 已被用作黏膜利什曼病的替代治疗方法，但最佳剂量尚未确定。我们回顾性分析了 8 例黏膜利什曼病患者接受脂质体两性霉素 B 治疗的临床结果。平均总剂量为 35mg/kg（范围 24-50mg/kg），所有患者的所有病变均治愈，随访期间无复发（平均 25 个月；范围 7-40 个月）。
相似文献
1
Can we use a lower dose of liposomal amphotericin B for the treatment of mucosal American leishmaniasis?我们能否使用更低剂量的脂质体两性霉素 B 来治疗黏膜型皮肤利什曼病？
Am J Trop Med Hyg. 2011 Nov;85(5):818-9. doi: 10.4269/ajtmh.2011.11-0287.
2
Liposomal formulation of amphotericin B for the treatment of mucosal leishmaniasis in HIV-negative patients.脂质体制剂两性霉素 B 治疗 HIV 阴性患者的黏膜利什曼病。
Trans R Soc Trop Med Hyg. 2014 Mar;108(3):176-8. doi: 10.1093/trstmh/tru011.
3
Efficacy and Safety of Liposomal Amphotericin B for the Treatment of Mucosal Leishmaniasis from the New World: A Retrospective Study.脂质体两性霉素 B 治疗新大陆黏膜利什曼病的疗效和安全性：一项回顾性研究。
Am J Trop Med Hyg. 2015 Dec;93(6):1214-8. doi: 10.4269/ajtmh.15-0033. Epub 2015 Oct 19.
4
Liposomal amphotericin B treatment of Old World cutaneous and mucosal leishmaniasis: A literature review.脂质体两性霉素B治疗旧世界皮肤和黏膜利什曼病：文献综述
Acta Trop. 2018 Jun;182:246-250. doi: 10.1016/j.actatropica.2018.03.016. Epub 2018 Mar 14.
5
[Treatment of the mucosal form of leishmaniasis without response to glucantime, with liposomal amphotericin B].[对葡甲胺无反应的黏膜利什曼病用脂质体两性霉素B治疗]
Rev Soc Bras Med Trop. 1997 Mar-Apr;30(2):125-8. doi: 10.1590/s0037-86821997000200007.
6
Use of amphotericin B in mucocutaneous leishmaniasis.两性霉素B在皮肤黏膜利什曼病中的应用。
J Trop Med Hyg. 1976 May;79(5):111-3.
7
Mucocutaneous leishmaniasis treated with liposomal amphotericin B.用脂质体两性霉素B治疗皮肤利什曼病。
Rev Soc Bras Med Trop. 2008 Jan-Feb;41(1):87-8. doi: 10.1590/s0037-86822008000100018.
8
Treatment of mucocutaneous (American) leishmaniasis with amphotericin B: report of 70 cases.两性霉素B治疗皮肤黏膜型（美洲型）利什曼病：70例报告
Int J Dermatol. 1971 Jul-Sep;10(3):179-81. doi: 10.1111/j.1365-4362.1971.tb01694.x.
9
Successful response to liposomal amphotericin B in mucosal leishmaniasis in glans resistant to intralesional pentavalent.对脂质体两性霉素B治疗阴茎头黏膜利什曼病有效，该阴茎头对病灶内注射五价锑剂耐药。
Int J Dermatol. 2019 Jul;58(7):e137-e138. doi: 10.1111/ijd.14432. Epub 2019 Mar 18.
10
Refractory mucocutaneous leishmaniasis resolved with combination treatment based on intravenous pentamidine, oral azole, aerosolized liposomal amphotericin B, and intralesional meglumine antimoniate.难治性黏膜皮肤利什曼病采用静脉注射戊烷脒、口服唑类药物、雾化脂质体两性霉素 B 和病灶内注射葡甲胺锑治疗后得到缓解。
Int J Infect Dis. 2020 Aug;97:204-207. doi: 10.1016/j.ijid.2020.06.003. Epub 2020 Jun 4.
引用本文的文献
1
Meglumine antimoniate was associated with a higher cure rate than liposomal amphotericin B in the treatment of American tegumentary leishmaniasis: A retrospective cohort study from a -endemic area.葡甲胺锑酸钠治疗皮肤利什曼病的治愈率高于脂质体两性霉素 B：来自流行地区的回顾性队列研究。
Front Cell Infect Microbiol. 2022 Sep 23;12:993338. doi: 10.3389/fcimb.2022.993338. eCollection 2022.
2
Liposomal drug delivery systems for the treatment of leishmaniasis.用于治疗利什曼病的脂质体药物传递系统。
Parasitol Res. 2022 Nov;121(11):3073-3082. doi: 10.1007/s00436-022-07659-5. Epub 2022 Sep 16.
3
Case Report: Cutaneous Leishmaniasis in a Rheumatoid Arthritis Patient Receiving Methotrexate.病例报告：接受甲氨蝶呤治疗的类风湿关节炎患者罹患皮肤利什曼病。
Am J Trop Med Hyg. 2022 Sep 6;107(4):785-788. doi: 10.4269/ajtmh.22-0180. Print 2022 Oct 12.
4
American cutaneous leishmaniasis in French Guiana: a retrospective comparison between liposomal amphotericin B and meglumine antimoniate.法属圭亚那的美洲皮肤利什曼病：两性霉素B脂质体与葡甲胺锑酸盐的回顾性比较
Br J Dermatol. 2020 Aug;183(2):389-391. doi: 10.1111/bjd.18964. Epub 2020 Mar 31.
5
Lipid nanoparticles for amphotericin delivery in the treatment of American tegumentary leishmaniasis.脂质纳米粒用于两性霉素递送治疗美洲皮肤利什曼病。
Drug Deliv Transl Res. 2020 Apr;10(2):403-412. doi: 10.1007/s13346-019-00677-4.
6
Comparative study on liposomal amphotericin B and other therapies in the treatment of mucosal leishmaniasis: A 15-year retrospective cohort study.脂质体两性霉素 B 与其他疗法治疗黏膜利什曼病的对比研究：一项 15 年回顾性队列研究。
PLoS One. 2019 Jun 26;14(6):e0218786. doi: 10.1371/journal.pone.0218786. eCollection 2019.
7
Secondary Prophylaxis with Liposomal Amphotericin B in a Patient with Mucosal Leishmaniasis Undergoing Immunobiological Therapy for Active Ankylosing Spondylitis.在接受免疫生物治疗的活动性强直性脊柱炎患者中，采用脂质体两性霉素 B 进行黏膜利什曼病的二级预防。
Am J Trop Med Hyg. 2019 Aug;101(2):402-403. doi: 10.4269/ajtmh.19-0066.
8
Review of the current treatments for leishmaniases.利什曼病当前治疗方法综述。
Res Rep Trop Med. 2012 Jul 26;3:69-77. doi: 10.2147/RRTM.S24764. eCollection 2012.
9
Treatment of mucosal leishmaniasis with amphotericin B lipid complex (ABLC).用两性霉素B脂质复合物（ABLC）治疗黏膜利什曼病。
Rev Inst Med Trop Sao Paulo. 2018 Nov 8;60:e71. doi: 10.1590/S1678-9946201860071.
10
Mucosal leishmaniasis mimicking T-cell lymphoma in a patient receiving monoclonal antibody against TNFα.一名接受抗TNFα单克隆抗体治疗的患者出现类似T细胞淋巴瘤的黏膜利什曼病。
PLoS Negl Trop Dis. 2017 Sep 21;11(9):e0005807. doi: 10.1371/journal.pntd.0005807. eCollection 2017 Sep.
本文引用的文献
1
Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial.印度内脏利什曼病短程多药治疗与标准治疗的比较：一项开放标签、非劣效性、随机对照试验。
Lancet. 2011 Feb 5;377(9764):477-86. doi: 10.1016/S0140-6736(10)62050-8. Epub 2011 Jan 20.
2
Mucosal leishmaniasis and abnormalities on computed tomographic scans of paranasal sinuses.黏膜利什曼病与副鼻窦计算机断层扫描异常。
Am J Trop Med Hyg. 2010 Sep;83(3):515-8. doi: 10.4269/ajtmh.2010.10-0081.
3
Mucosal leishmaniasis: description of case management approaches and analysis of risk factors for treatment failure in a cohort of 140 patients in Brazil.黏膜利什曼病：巴西140例患者队列中病例管理方法的描述及治疗失败风险因素分析
J Eur Acad Dermatol Venereol. 2009 Sep;23(9):1026-34. doi: 10.1111/j.1468-3083.2009.03238.x. Epub 2009 May 4.
4
Cutaneous leishmaniasis.皮肤利什曼病
Lancet Infect Dis. 2007 Sep;7(9):581-96. doi: 10.1016/S1473-3099(07)70209-8.
5
Treatment of mucosal leishmaniasis in Latin America: systematic review.拉丁美洲黏膜利什曼病的治疗：系统评价
Am J Trop Med Hyg. 2007 Aug;77(2):266-74.
6
Liposomal amphotericin B for the treatment of visceral leishmaniasis.脂质体两性霉素B用于治疗内脏利什曼病。
Clin Infect Dis. 2006 Oct 1;43(7):917-24. doi: 10.1086/507530. Epub 2006 Aug 28.
7
Amphotericin B tissue distribution in autopsy material after treatment with liposomal amphotericin B and amphotericin B colloidal dispersion.脂质体两性霉素B和两性霉素B胶体分散体治疗后尸检材料中两性霉素B的组织分布。
J Antimicrob Chemother. 2006 Jun;57(6):1153-60. doi: 10.1093/jac/dkl141. Epub 2006 Apr 20.
8
Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations.两性霉素B治疗印度内脏利什曼病：传统剂型与脂质体制剂对比
Clin Infect Dis. 2004 Feb 1;38(3):377-83. doi: 10.1086/380971. Epub 2004 Jan 13.
9
Mucocutaneous leishmaniasis associated with HIV infection treated successfully with liposomal amphotericin B (AmBisome).
J Antimicrob Chemother. 2000 Aug;46(2):341-2. doi: 10.1093/jac/46.2.341.
10
Mucosal leishmaniasis unresponsive to glucantime therapy successfully treated with AmBisome.
Trans R Soc Trop Med Hyg. 1997 Jan-Feb;91(1):77. doi: 10.1016/s0035-9203(97)90404-1.
Zotero 插件